Anti-inflammatory Therapeutics Market By Indication (arthritis, Respiratory Diseases, Multiple Sclerosis, Psoriasis, Inflammatory/bowel Disease & Other Inflammatory Diseases) And Drug Class (anti-inflammatory Biologics, Non-steroidal Anti-inflammatory Drugs (nsaids) & Corticosteroids)- Global Industry Analysis And Forecast To 2023
Published On : June 2022 Pages : 190 Category: Pharmaceuticals Report Code : HC061032
Industry Outlook and Trend Analysis
Anti-inflammatory Therapeutics Market was worth USD 71.47 billion in 2017 and is expected to reach approximately USD 118.81 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 5.81% during the forecast period. Inflammation is a complicated reaction of the body towards damaged cells, pathogens or any external foreign material. It is identified by redness, swelling, pain and now and then loss of capacity of the inflamed part. Inflammation is of two kinds: chronic and acute. The chronic ones are inflammations that last over a longer period of time principally observed in immune system ailments including rheumatoid arthritis (RA) and allergies. Whereas acute inflammations emerge from cut or scrap in the skin or diseases, for example, bronchitis which last for a shorter period and its effects lessen following couple of days. Anti-inflammatory medications are also known as non-steroidal anti-inflammatory drugs (NSAIDs) and are therapeutic medications which are utilized to treat pain, lessen swelling and other long term chronic torments related with inflammation.
Indication Outlook and Trend Analysis
Based on indication the IBD (Inflammatory bowel disease) is the leading segment in the market. As indicated by CDC (Centers for Disease Control and Prevention), in the US, it is anticipated that around 1 Mn to1.3 Mn individuals are struck by IBD. In addition, reports from different countries show that the rate of IBD is developing, especially in youth. Presently, the highest yearly frequency of IBD in Europe was 12.7 for each 100,000 person-years for CD (Crohn's Disease) and 24.3 for each 100,000 person-years for UC (Ulcerative Colitis).
Drug Class Outlook and Trend Analysis
Currently, corticosteroids are the biggest drug type on the basis of value and assessed to hold its conspicuousness and biologics to record most elevated twofold digit CAGR all through the estimate time frame. As per WHO the pervasiveness of rheumatoid arthritis varies between 0.3% and 1% which is more common in women.
Regional Outlook and Trend Analysis
North America has developed as the main portion of the anti-inflammatory therapeutics market. The advent of cutting edge anti-inflammatory therapeutics has energized more prominent acknowledgment of these medications by buyers in North America. With Germany, France, Spain, Spain, UK and Italy being the key contributors, the anti-inflammatory therapeutics market in Europe is likewise anticipated that would prosper. Nonetheless, Asia Pacific is anticipated to rise as the quickest developing regional market, driven by a huge patient pool, expanding disposable earnings, increasing health awareness, and development in the healthcare infrastructure.
Competitive Insights
The major players in the market are AstraZeneca, Merck & Co, Roche Holding AG, AbbVie Inc, Novartis, Pfizer, Amgen, Johnson & Johnson, Eli Lilly and Company and GlaxoSmithKline. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
The Anti-inflammatory Therapeutics Market is segmented as follows-
By Indication
- Arthritis,
- Respiratory Diseases
- Multiple Sclerosis
- Psoriasis
- Inflammatory/Bowel Disease
- Other inflammatory Diseases
By Drug Class
- Anti-inflammatory Biologics
- Non-Steroidal Anti-inflammatory drugs (NSAIDs)
- Corticosteroids
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- South Africa
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2023?
- What will be the industry market growth from 2017 to 2023?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Anti-Inflammatory Therapeutics Market, By Indication, Estimates and Forecast, 2014-2023 ($Million)
· Arthritis
· Respiratory Diseases
· Multiple Sclerosis
· Psoriasis
· Inflammatory/Bowel Disease
· Other inflammatory Diseases
· Anti-Inflammatory Therapeutics Market, By Drug Class, Estimates and Forecast, 2014-2023 ($Million)
· Anti-inflammatory Biologics
· Non-Steroidal Anti-inflammatory drugs (NSAIDs)
· Corticosteroids
· Anti-Inflammatory Therapeutics Market, By Region, Estimates and Forecast, 2014-2023 ($Million)
· North America
§ North America Anti-Inflammatory Therapeutics Market, By Country
o U.S. Anti-Inflammatory Therapeutics Market
o Canada Anti-Inflammatory Therapeutics Market
o Mexico Anti-Inflammatory Therapeutics Market
· Europe
§ Europe Anti-Inflammatory Therapeutics Market, By Country
o Germany Anti-Inflammatory Therapeutics Market
o UK Anti-Inflammatory Therapeutics Market
o France Anti-Inflammatory Therapeutics Market
o Russia Anti-Inflammatory Therapeutics Market
o Italy Anti-Inflammatory Therapeutics Market
o Rest of Europe Anti-Inflammatory Therapeutics Market
· Asia-Pacific
§ Asia-Pacific Anti-Inflammatory Therapeutics Market, By Country
o China Anti-Inflammatory Therapeutics Market
o Japan Anti-Inflammatory Therapeutics Market
o South Korea Anti-Inflammatory Therapeutics Market
o India Anti-Inflammatory Therapeutics Market
o Southeast Asia Anti-Inflammatory Therapeutics Market
o Rest of Asia-Pacific Anti-Inflammatory Therapeutics Market
· South America
§ South America Anti-Inflammatory Therapeutics Market
o Brazil Anti-Inflammatory Therapeutics Market
o Argentina Anti-Inflammatory Therapeutics Market
o Columbia Anti-Inflammatory Therapeutics Market
o South Africa Anti-Inflammatory Therapeutics Market
o Rest of South America Anti-Inflammatory Therapeutics Market
· Middle East and Africa
§ Middle East and Africa Anti-Inflammatory Therapeutics Market
o Saudi Arabia Anti-Inflammatory Therapeutics Market
o UAE Anti-Inflammatory Therapeutics Market
o Egypt Anti-Inflammatory Therapeutics Market
o Nigeria Anti-Inflammatory Therapeutics Market
o South Africa Anti-Inflammatory Therapeutics Market
o Rest of MEA Anti-Inflammatory Therapeutics Market
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market States and Outlook (2017-2023)
4.1.2. Canada Market States and Outlook (2017-2023)
4.1.3. Mexico Market States and Outlook (2017-2023)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market States and Outlook (2017-2023)
4.2.2. France Market States and Outlook (2017-2023)
4.2.3. UK Market States and Outlook (2017-2023)
4.2.4. Russia Market States and Outlook (2017-2023)
4.2.5. Italy Market States and Outlook (2017-2023)
4.2.6. Rest of Europe Market States and Outlook (2017-2023)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market States and Outlook (2017-2023)
4.3.2. Japan Market States and Outlook (2017-2023)
4.3.3. Korea Market States and Outlook (2017-2023)
4.3.4. India Market States and Outlook (2017-2023)
4.3.5. Rest of Asia-Pacific Market States and Outlook (2017-2023)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market States and Outlook (2017-2023)
4.4.2. Argentina Market States and Outlook (2017-2023)
4.4.3. Columbia Market States and Outlook (2017-2023)
4.4.4. Rest of South America Market States and Outlook (2017-2023)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market States and Outlook (2017-2023)
4.5.2. UAE Market States and Outlook (2017-2023)
4.5.3. Egypt Market States and Outlook (2017-2023)
4.5.4. Nigeria Market States and Outlook (2017-2023)
4.5.5. South Africa Market States and Outlook (2017-2023)
4.5.6. Rest of MEA Market States and Outlook (2017-2023)
5. Anti-Inflammatory Therapeutics Market, By Indication
5.1. Introduction
5.2. Global Anti-Inflammatory Therapeutics Revenue and Market Share by Indication (2017-2027)
5.2.1. Global Anti-Inflammatory Therapeutics Revenue and Revenue Share by Indication (2017-2027)
5.3. Arthritis
5.3.1. Global Arthritis Revenue and Growth Rate (2017-2027)
5.4. Respiratory Diseases
5.4.1. Global Respiratory Diseases Revenue and Growth Rate (2017-2027)
5.5. Multiple Sclerosis
5.5.1. Global Multiple Sclerosis Revenue and Growth Rate (2017-2027)
5.6. Psoriasis
5.6.1. Global Psoriasis Revenue and Growth Rate (2017-2027)
5.7. Inflammatory/Bowel Disease
5.7.1. Global Inflammatory/Bowel Disease Revenue and Growth Rate (2017-2027)
5.8. Other inflammatory Diseases
5.8.1. Global Other inflammatory Diseases Revenue and Growth Rate (2017-2027)
6. Anti-Inflammatory Therapeutics Market, By Drug Class
6.1. Introduction
6.2. Global Anti-Inflammatory Therapeutics Revenue and Market Share by Drug Class (2017-2027)
6.2.1. Global Anti-Inflammatory Therapeutics Revenue and Revenue Share by Drug Class (2017-2027)
6.3. Anti-inflammatory Biologics
6.3.1. Global Anti-inflammatory Biologics Revenue and Growth Rate (2017-2027)
6.4. Non-Steroidal Anti-inflammatory drugs (NSAIDs)
6.4.1. Global Non-Steroidal Anti-inflammatory drugs (NSAIDs) Revenue and Growth Rate (2017-2027)
6.5. Corticosteroids
6.5.1. Global Corticosteroids Revenue and Growth Rate (2017-2027)
7. Anti-Inflammatory Therapeutics Market, By Region
7.1. Introduction
7.2. Global Anti-Inflammatory Therapeutics Revenue and Market Share by Regions
7.2.1. Global Anti-Inflammatory Therapeutics Revenue by Regions (2017-2027)
7.3. North America Anti-Inflammatory Therapeutics by Countries
7.3.1. North America Anti-Inflammatory Therapeutics Revenue and Growth Rate (2017-2027)
7.3.2. North America Anti-Inflammatory Therapeutics Revenue by Countries (2017-2027)
7.3.3. North America Anti-Inflammatory Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.3.4. U.S.
7.3.4.1. United States Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Canada
7.3.5.1. Canada Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.6. Mexico
7.3.6.1. Mexico Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Anti-Inflammatory Therapeutics by Countries
7.4.1. Europe Anti-Inflammatory Therapeutics Revenue and Growth Rate (2017-2027)
7.4.2. Europe Anti-Inflammatory Therapeutics Revenue by Countries (2017-2027)
7.4.3. Europe Anti-Inflammatory Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.4.4. Germany
7.4.4.1. Germany Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. France
7.4.6.1. France Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Russia
7.4.7.1. Russia Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Italy
7.4.8.1. Italy Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.9. Rest of Europe
7.4.9.1. Rest of Europe Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific
7.5.1. Asia-Pacific Anti-Inflammatory Therapeutics Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Anti-Inflammatory Therapeutics Revenue by Countries (2017-2027)
7.5.3. Asia-Pacific Anti-Inflammatory Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.5.4. China
7.5.4.1. China Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Japan
7.5.5.1. Japan Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5.2.
7.5.6. Korea
7.5.6.1. Korea Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. India
7.5.7.1. India Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Southeast Asia
7.5.8.1. Southeast Asia Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.9. Rest of Asia-Pacific
7.5.9.1. Rest of Asia-Pacific Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America
7.6.1. South America Anti-Inflammatory Therapeutics Revenue and Growth Rate (2017-2027)
7.6.2. South America Anti-Inflammatory Therapeutics Revenue by Countries (2017-2027)
7.6.3. South America Anti-Inflammatory Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.6.4. Brazil
7.6.4.1. Brazil Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Argentina
7.6.5.1. Argentina Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Columbia
7.6.6.1. Columbia Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.7. Rest of South America
7.6.7.1. Rest of South America Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa
7.7.1. Middle East and Africa Anti-Inflammatory Therapeutics Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Anti-Inflammatory Therapeutics Revenue by Countries (2017-2027)
7.7.3. Middle East and Africa Anti-Inflammatory Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.7.4. Saudi Arabia
7.7.4.1. Saudi Arabia Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. United Arab Emirates
7.7.5.1. United Arab Emirates Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Egypt
7.7.6.1. Egypt Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. Nigeria
7.7.7.1. Nigeria Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. South Africa
7.7.8.1. South Africa Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Pfizer, Inc.
8.1.1. Business Overview
8.1.2. Indication Portfolio
8.1.3. Strategic Developments
8.1.4. Revenue and Market Share
8.2. Amgen, Inc.
8.2.1. Business Overview
8.2.2. Indication Portfolio
8.2.3. Strategic Developments
8.2.4. Revenue and Market Share
8.3. AstraZeneca plc
8.3.1. Business Overview
8.3.2. Indication Portfolio
8.3.3. Strategic Developments
8.3.4. Revenue and Market Share
8.4. Eli Lily and Company
8.4.1. Business Overview
8.4.2. Indication Portfolio
8.4.3. Strategic Developments
8.4.4. Revenue and Market Share
8.5. GlaxoSmithKline plc
8.5.1. Business Overview
8.5.2. Indication Portfolio
8.5.3. Strategic Developments
8.5.4. Revenue and Market Share
8.6. Johnson & Johnson
8.6.1. Business Overview
8.6.2. Indication Portfolio
8.6.3. Strategic Developments
8.6.4. Revenue and Market Share
8.7. Merck & Company, Inc.
8.7.1. Business Overview
8.7.2. Indication Portfolio
8.7.3. Strategic Developments
8.7.4. Revenue and Market Share
8.8. Novartis International AG
8.8.1. Business Overview
8.8.2. Indication Portfolio
8.8.3. Strategic Developments
8.8.4. Revenue and Market Share
8.9. AbbVie Inc
8.9.1. Business Overview
8.9.2. Indication Portfolio
8.9.3. Strategic Developments
8.9.4. Revenue and Market Share
8.10. F. Hoffmann-La Roche AG
8.10.1. Business Overview
8.10.2. Indication Portfolio
8.10.3. Strategic Developments
8.10.4. Revenue and Market Share
9. Global Anti-Inflammatory Therapeutics Market Competition, by Manufacturer
9.1. Global Anti-Inflammatory Therapeutics Revenue and Market Share by Manufacturer (2017-2017)
9.2. Global Anti-Inflammatory Therapeutics Price by Region (2017-2017)
9.3. Top 5 Anti-Inflammatory Therapeutics Manufacturer Market Share
9.4. Market Competition Trend
10. Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.1. Global Anti-Inflammatory Therapeutics Revenue (Millions USD) and Growth Rate (2027-2023)
10.2. Anti-Inflammatory Therapeutics Market Forecast by Regions (2027-2023)
10.2.1. North America Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.1.1. United States Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.1.2. Canada Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.1.3. Mexico Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.2. Europe Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.2.1. Germany Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.2.2. United Kingdom Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.2.3. France Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.2.4. Russia Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.2.5. Italy Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.2.6. Rest of the Europe Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.3. Asia-Pacific Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.3.1. China Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.3.2. Japan Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.3.3. Korea Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.3.4. India Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.3.5. Southeast Asia Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.3.6. Rest of Asia-Pacific Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.4. South America Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.4.1. Brazil Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.4.2. Argentina Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.4.3. Columbia Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.4.4. Rest of South America Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.5. Middle East and Africa Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.5.1. Saudi Arabia Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.5.2. UAE Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.5.3. Egypt Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.5.4. Nigeria Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.5.5. South Africa Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.2.5.6. Rest of MEA Anti-Inflammatory Therapeutics Market Forecast (2027-2023)
10.3. Anti-Inflammatory Therapeutics Market Forecast by Indication (2027-2023)
10.3.1. Global Anti-Inflammatory Therapeutics Revenue Forecast by Indication (2027-2023)
10.3.2. Global Anti-Inflammatory Therapeutics Revenue Market Share Forecast by Indication (2027-2023)
10.4. Anti-Inflammatory Therapeutics Market Forecast by Drug Class (2027-2023)
10.4.1. Global Anti-Inflammatory Therapeutics Revenue Forecast by Drug Class (2027-2023)
10.4.2. Global Anti-Inflammatory Therapeutics Revenue Market Share Forecast by Drug Class (2027-2023)
10.5. Anti-Inflammatory Therapeutics Market Forecast by Technology (2027-2023)
10.5.1. Global Anti-Inflammatory Therapeutics Revenue Forecast by Technology (2027-2023)
10.5.2. Global Anti-Inflammatory Therapeutics Revenue Market Share Forecast by Technology (2027-2023)
List of Tables
*You can glance through the list of Tables and Figures when you view the sample copy of Anti-Inflammatory Therapeutics Market.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|